About ADx NeuroSciences
ADx NeuroSciences is a company based in Ghent (Belgium) founded in 2011. ADx NeuroSciences has raised $3.17 million across 4 funding rounds from investors including European Union. The company has 14 employees as of December 31, 2021. ADx NeuroSciences offers products and services including Biomarker Assays and Tailor-made Antibodies. ADx NeuroSciences operates in a competitive market with competitors including Cytox, Amprion, PeopleBio R&D, Durin Technologies and Adlyfe, among others.
- Headquarter Ghent, Belgium
- Employees 14 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adx Neurosciences
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.17 M (USD)
in 4 rounds
-
Latest Funding Round
$588.08 K (USD), Grant
Nov 01, 2019
- Investors
-
Employee Count
14
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ADx NeuroSciences
ADx NeuroSciences offers a comprehensive portfolio of products and services, including Biomarker Assays and Tailor-made Antibodies.
Assays for quantifying biomarkers in neurodegenerative diseases
Custom antibodies for detecting specific disease markers
Funding Insights of ADx NeuroSciences
ADx NeuroSciences has successfully raised a total of $3.17M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $588.08 thousand completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ADx NeuroSciences
ADx NeuroSciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for ADx NeuroSciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ADx NeuroSciences
Investment portfolio details for ADx NeuroSciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ADx NeuroSciences
Detailed financials for ADx NeuroSciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adx Neurosciences Comparisons
Peer comparison for ADx NeuroSciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ADx NeuroSciences
ADx NeuroSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytox, Amprion, PeopleBio R&D, Durin Technologies and Adlyfe, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Prognostic tests for assessing dementia risk are developed.
|
|
| Locked | Locked | Locked |
Assay technology for misfolded proteins in neurodegenerative disorders is developed.
|
|
| Locked | Locked | Locked |
Immunoassays are developed for early detection of neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Developer of the diagnostic test for neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Develops biomarkers and diagnostic tests for amyloid-related diseases.
|
Detailed competitors of ADx NeuroSciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adx Neurosciences
Complete news archive for ADx NeuroSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADx NeuroSciences
ADx NeuroSciences was founded in 2011 and raised its 1st funding round 1 year after it was founded.
ADx NeuroSciences is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
ADx NeuroSciences is a funded company, having raised a total of $3.17M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at ADx NeuroSciences is 14.
ADx NeuroSciences was founded in 2011 in Ghent, Belgium, within the biotechnology sector focused on neurodegenerative diseases. Biomarker assays are developed to detect indicators such as beta amyloid and tau in patient fluid samples, primarily cerebrospinal fluid, with emerging blood-based tests. Panels target Alzheimers disease, alongside Parkinsons disease, traumatic brain injury, and amyotrophic lateral sclerosis. Partnerships are maintained with Quanterix, Lilly, TauRx, and EuroImmun to support assay advancement.
ADx NeuroSciences's top competitors include Amprion, PeopleBio R&D and Cytox.
ADx NeuroSciences offers Biomarker Assays and Tailor-made Antibodies.
ADx NeuroSciences has 1 investor. Key investors include European Union.